Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-08-03
2004-03-23
Harris, Alana M. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S007200, C435S007240, C436S063000, C436S064000, C436S501000, C436S503000, C530S350000, C530S385000, C530S386000, C530S388100, C530S388800, C530S388850
Reexamination Certificate
active
06709832
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method for the early diagnosis of carcinomas as well as their preliminary stages, particularly carcinomas of the upper respiratory tract or the anogenital tract.
BACKGROUND OF THE INVENTION
Preventive programs have been offered for the most differing carcinomas since the middle of the 50ies. Regarding the cervical carcinoma they are based mainly on the morphological and cytological examination of cytosmears of the cervix uteri, what is called the Pap test, which is made on the basis of gynecological routine examinations at regular intervals in women from the 20
th
year on. By means of the morphology of the cells, the smears are divided into various intensity degrees of dysplastic cellular changes. According to Pap I-V, these intensity degrees are referred to as normal, mild dysplasia, fairly serious dysplasia, serious dysplasia and invasive carcinoma, respectively. If the Pap test leads to a striking result, a small biopsy will be taken and subjected to a histopathologic examination, by which the kind and intensity of the dysplasia are determined and classified as cervical intraepithelial neoplasia (CINI-III).
In spite of all preventive programs, the cervical carcinoma which leads to 400,000 new cases per year is the: most frequent carcinoma in women. This is inter alia due to the fact that up to 30% of the Pap test results are false-negative.
Therefore, it is the object of the present invention to provide a method by which cervical carcinomas can be diagnosed early and reliably. In addition, a differentiation should be possible by this method with respect to benign inflammatory or metaplastic changes of dysplastic preneoplasias.
According to the invention, this is achieved by the subject matters defined in the claims.
SUMMARY OF THE INVENTION
The present invention is based on the applicant's insights that cell cycle regulatory proteins are overexpressed in many carcinomas, e.g., carcinomas of the upper respiratory tract or anogenital carcinomas, particularly cervical carcinoma, and preliminary stages of these carcinomas. Examples of the cell cycle regulatory proteins are cyclins. Cyclin-dependent kinases which regulate the cyclins are to be mentioned particularly. Cyclin-dependent kinase inhibitors which, in turn, regulate the cyclin-dependent kinases, are to be mentioned even more particularly. Examples of the cyclin-dependent kinase inhibitors are the proteins p14, p15, p16, p19, p21 and p27. The applicant has found that the intensity of cell cycle regulatory protein overexpression correlates with the degree of cell dysplasia.
REFERENCES:
patent: 5976799 (1999-11-01), O'Brien et al.
patent: 6287775 (2001-09-01), O'Brien et al.
patent: WO 94/09135 (1994-04-01), None
patent: WO 94/12881 (1994-06-01), None
patent: WO 94/17414 (1994-08-01), None
Geradts, Joseph, et al.,Cancer Research, Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Product p16INK4A in Archival Human Solid Tumors: Correlation with Retinoblastoma Protein Expression (1995) 55 (6006-6011).
Hirama, Toshiyasu, et al.,Modern Pathology, (1996), 9/1 (26-31), p16 (CDKN2/Cyclin-dependent Kinase-4 Inhibitor/Multiple Tumor Suppressor-1) Gene Is Not Altered in Uterine Cervical Carcinomas or Cell Lines.
Kelley, Michael J., et al.,International Journal of Cancer, (1995) 63/2 (226-230), CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.
Kim, et al.,Experimental and Molecular Medicine, (Jun. 30, 1998) 30/2 (109-113), Alterations of CDKN2 (MTS1/p16(INK4A) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers.
Kim, et al.,Gynecologic Oncology, (1998) 71/1 (38-45), Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma, (concludes that the CDK inhibitors (including p16) are significantly decreased in cervical carcinoma tissues.
Kim, et al.,Gynecologic Oncology, (1998) 70 (75-79), Absence of p15INK4B and p16INK4A Gene Alterations in Primary Cervical Carcinoma Tissues and Cell Lines with Human Papillomavirus Infection.
Klaes, Ruediger, et al.,Int. J. Cancer, (2001) 92 (276-284), Overexpression of p16INK4A As A Specific Marker For Dysplastic And Neoplastic Epithelial Cells Of The Cervix Uteri.
Milde-Langosch, et al.,Int. J. Cancer, (1988) 79(1) (61-65), p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.
Milde-Langosch, et al.,Virchows Archiv, (1999) 434/1 (23-28), P16/MTS1 and pRB expression in endometrial carcinomas.
Nuovo, et al.,Proceedings of the National Academy of Sciences of the United States of America(Oct. 26, 1999) 96/22 (12754-12759), In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis.
Sano, Takaaki, et al.,Pathology International(1998) 48 (580-585); Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia.
Sano, Takaaki, et al.,American Journal of Pathology, (1998) 153/6 (1741-1448), Expression Status of p16 Protein Is Associated with Huma Papillomavirus Oncogenic Potentila in Cervical and Genital Lesions.
Shigemasa, K., et al.,J. Soc. Gynecol Invest, (1997) 4/2 (95-102), p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma.
Shim, et al.,Clinical Cancer Research, (1998) 4/12 (3045-3050), Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array.
Tam, S.W., et al.,Cancer Res., (1994) 54/22 (5816-5820), Differential expresionand cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4.
Wong, Y.F., et al.,Gynecol Oncol(1997) 65/2 (319-324), p16INK4 and p15INK4B alterations in primary gynecologic malignancy.
Wong, Y.F., et al.,Cancer Letters, (1999) 136/2 (231-235), Methylation of p16(INK4A) in primary gynecologic malignancy.
Li et al. Zhonghua Zhongliu Zazhi 19/4:306-308, Jul. 1997.*
Gemma et al. (International Journal of Cancer 68:605-611, 1996.*
Su et al. Journal of China Medical University 27/4:394-396, Aug. 1998.*
Balazs et al. Genes, Chromosomes and Cancer 19 :84-89, 1997.*
Perry et al. Journal of Neuropathology and Experimental Neurology 56/9:999-1008, Sep. 1997.*
Shiohara et al. Leukemia 10:1897-1900, 1996.*
Ferrando et al. Hum Genet 97:91-94, 1996.*
Kawamata et al. Cancer 77/3:570-575, Feb. 1996.*
Huang et al. Hua Xi Yi De Da Xue Xue Bao, 23/1:61-64, Mar. 1992.*
Tron et al. American Journal of Pathology, 149/4:1139-1146, Oct. 1996.*
Mugikura et al. Sapporo Med. Journal 60/2:139-148, 1991.*
D.C. Betticher, et al., “Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell-lung cancer,”Br. J. Cancer, 73(3) 294-300 (1996).
V. Esposito, et al., “Prognostic Role of the Cyclin-dependent Kinase Inhibitor p27 in Non-Small Cell Lung Cancer,” abstract XP002912136, Aug. 15, 1997.
M. Kania, et al. “Immunohistochemical Detection of Sex Steroid Receptors, Cyclins, and Cyclin-Dependent Kinases in the Normal and Neoplastic Squamous Epithelia of the Uterine Cervix”,Cancer, 82(9):1709-1719 (1998).
Y. Murakami and T, Sekiya, “Accumulation of genetic alterations and their significance in each primary human cancer and cell line,”Mutation Research, 400(1-2):421-437 (1998).
G.E. Nichols, et al., “Cyclin D1 Gene Expression in Human Cervical Neoplasia,”Modern Pathology, 9(4): 418-425 (1996).
I. Orlow, et al., “Cyclin-dependent Kinase Inhibitor p57KIP2in Soft Tissue Scarcomas and Wilms' Tumors,”Cancer Research, 56(6):1219-1221 (1996).
I.E. Shcauer, et al., “Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell lung cancer,”Proc. Natl. Acad. Sci., 91(16):7827-7831 (1994).
T. Zhang, et al., “Concurrent Overexpression of Cyclin D1 and Cyclin-dependent Kinase 4 (Cdk4) in Intestinal Adenomas from Multiple Intestinal Neoplasia (Min
Doeberitz Magnus Von Knebel
Spitkovsky Dimitry
Halluin Albert P.
Harris Alana M.
Howrey Simon Arnold & White , LLP
Kung Viola T.
Von Knebel Doeberitz Magnus
LandOfFree
Method of early diagnosis of carcinomas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of early diagnosis of carcinomas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of early diagnosis of carcinomas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3237480